PT Staff

The FDA approved a molecular test for emergency use and a supplemental new drug application for a blood sugar medication.

The novel antibiotic combines aztreonam, a monobactam β-lactam, with avibactam, a broad-spectrum β-lactamase inhibitor.

Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.

Clinicians are increasingly recognizing the negative impact of the middle-of-the-night dosing required with twice-nightly therapies for narcolepsy.

CCR5 mutation creates a challenge for HIV to infect more cells, thereby creating resistance to the virus.

Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.

Research notes that modifiable lifestyle factors, such as overconsumption of food and vitamin deficiency, can affect pregnancy.

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Products include a new FDA-approved treatment for dermatitis in younger individuals and a continuous glucose monitoring sensor system.

Products include a 3-in-1 probiotic product and OTC hearing aids.

In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.

Study finds that a more accurate estimate of the burden of RSV disease will facilitate appropriate decision making regarding the use of preventive interventions, such as vaccination.

Study findings may help guide efforts to develop effective HIV vaccines and antibody-based HIV treatments.

Pegfilgrastim-pbbk is a leukocyte growth factor developed to reduce the onset of infection in patients with non-myeloid malignancies administered myelosuppressive anticancer medications associated with a clinically significant rate of febrile neutropenia.

Study evaluates the effect of long-acting monoclonal antibodies tixagevimab and cilgavimab treating COVID-19 symptoms and viral shedding.

Study shows that the nervous system of individuals experiencing post-COVID-19 fatigue is underactive in 3 key areas.

An FDA committee voted 17-0 to make the once-daily birth control medication Opill available OTC after deciding the benefits outweigh any potential harms.

Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Prevnar 20 is a next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13.

PT highlights products from Zydus Lifesciences and Lupin.

Products include deodorant and pain medication that uses a plant-based formula.

Products include treatment for major depressive disorder and severe asthma.

VAX-24 is designed to prevent invasive pneumococcal disease and pneumonia, which can be most serious for infants, young children, older adults, and those with immune deficiencies or some chronic health conditions.

Atogepant (Qulipta; AbbVie) is the first and only oral calcitonin gene-related peptide receptor antagonist to gain FDA approval for the prevention of episodic and chronic migraine.

Similarities between the symptoms of Clostridioides difficile infection and Crohn disease may cause confusion for health care providers.

Accelerated approvals for ibrutinib (Imbruvica) for patients with mantle cell lymphoma and with marginal zone lymphoma voluntarily withdrawn based on data that were insufficient to support conversion to full approval.

Enfortumab vedotin-ejfv (Padcev, Astellas Pharma and Seagen Inc) with pembrolizumab (Keytruda, Merck) approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

Products include an as needed treatment for bronchoconstriction and a treatment for Alzheimer disease.

Quantitative polymerase chain reaction methods that are validated to determine bacterial load are important for assessing the impact of vaccines in public health programs.